Clinical Trials Browser

Unknown × Carcinoma, Non-Small-Cell Lung × pembrolizumab × Clear all

NCT05418660 2023-09-18

I-STOP

Carcinoma, Non-Small-Cell Lung

NCT05739006 2023-08-02

Clinical Trial to Evaluate the PK and Safety of BCD-201 and Keytruda® in Patients With Advanced Malignancies

Phase 1 Unknown

DermatologicThoracic

Carcinoma, Non-Small-Cell Lung, Melanoma

NCT04638582 2023-03-22

Pembrolizumab as Neoadjuvant Therapy for Resectable Stage IA3 to IIA Non-Small Cell Lung Cancer (NSCLC)

Phase 2 Unknown

Carcinoma, Non-Small-Cell Lung

NCT05042375 2022-11-17

A Trial of Camrelizumab Combined With Famitinib Malate in Treatment Naïve Subjects With PD-L1-Positive Recurrent or Metastatic Non-Small Cell Lung Cancer

Phase 3 Unknown

Carcinoma, Non-Small-Cell Lung

NCT04571632 2022-09-14

Luscid

Phase 2 Unknown

Carcinoma, Non-Small-Cell Lung

NCT04989322 2021-12-08

Pembrolizumab, Lenvatinib and Chemotherapy After TKIs in NSCLC

Phase 2 Unknown

Carcinoma, Non-Small-Cell Lung

NCT04586465 2021-08-24

DYNAPET

Phase 2 Unknown

Carcinoma, Non-Small-Cell Lung

NCT04465942 2021-08-23

Immunotherapy in Lung Cancer: Treatment After IO Cessation.

Carcinoma, Non-Small-Cell Lung

NCT05008861 2021-08-17

Gut Microbiota Reconstruction for NSCLC Immunotherapy

Phase 1 Unknown

Carcinoma, Non-Small-Cell Lung

NCT02824965 2021-07-07

Pembrolizumab + CVA21 in Advanced NSCLC

Phase 1 Unknown

Carcinoma, Non-Small-Cell Lung

NCT03447678 2021-06-09

PEOPLE

Phase 2 Unknown

Carcinoma, Non-Small-Cell Lung

NCT03373955 2021-03-18

A Prospective Study of Constructing Immune Repertoire to Monitor the Therapeutic Effect in NSCLC Patients

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT04393883 2020-11-30

A Study With Pembrolizumab for Non-small Cell Lung Cancer (NSCLC)

Phase NA Unknown

Carcinoma, Non-Small-Cell Lung

NCT03544723 2020-06-09

Safety and Efficacy of p53 Gene Therapy Combined With Immune Checkpoint Inhibitors in Solid Tumors.

Phase 2 Unknown

BreastDermatologicGastrointestinalGenitourinaryGynecologicLymphoidThoracic

Carcinoma, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Uterine Cervical Neoplasms, Esophageal Neoplasms, Hodgkin Disease, Liver Neoplasms, Lymphoma, Melanoma, Stomach Neoplasms, Carcinoma, Merkel Cell, Neoplasms, Squamous Cell, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms

NCT04115410 2020-05-28

PD-1 Immune Checkpoint Inhibitors and Immune-Related Adverse Events: a Cohort Study

Carcinoma, Non-Small-Cell Lung

NCT04252365 2020-02-05

Sintilimab Versus Pembrolizumab for Advanced-stage Non-Small-Cell Lung Cancer

Phase 2 Unknown

Carcinoma, Non-Small-Cell Lung

NCT03396497 2019-09-25

Study of LYC-55716 With Pembrolizumab in Adult Subjects With Non-Small Cell Lung Cancer

Phase 1 Unknown

Carcinoma, Non-Small-Cell Lung

NCT03525782 2018-05-16

Anti-MUC1 CAR T Cells and PD-1 Knockout Engineered T Cells for NSCLC

Phase 1/2 Unknown

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT02758587 2018-03-19

Study of FAK (Defactinib) and PD-1 (Pembrolizumab) Inhibition in Advanced Solid Malignancies (FAK-PD1)

Phase 1/2 Unknown

GastrointestinalOther solid neoplasmThoracic

Carcinoma, Non-Small-Cell Lung, Mesothelioma, Pancreatic Neoplasms

NCT03446911 2018-02-27

Combining SBRT and Immunotherapy in Early Stage NSCLC Patients Planned for Surgery

Phase 1/2 Unknown

Carcinoma, Non-Small-Cell Lung

NCT03065764 2017-08-17

89Zr-labeled Pembrolizumab in Patients With Non-small-cell Lung Cancer

Phase 2 Unknown

Carcinoma, Non-Small-Cell Lung

NCT03053856 2017-02-15

Adjuvant Pembrolizumab in N2 Positive Non-small Cell Lung Cancer Patients

Phase 2 Unknown

Carcinoma, Non-Small-Cell Lung